Today: 27 December 2025
Subscribe
Browse Category

NYSE:ABT News 7 July 2025 - 25 December 2025

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Dec. 25, 2025 — Abbott Laboratories (NYSE: ABT) heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has (1) secured U.S. FDA approval
25 December 2025
 ·  ·  ·  ·  · 
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories (NYSE: ABT) finished Christmas Eve trading modestly higher, then ticked up again in light after-hours action—an unsurprising pattern for a defensive healthcare name during a holiday-shortened session. Still, the setup into Friday’s reopening (Dec. 26, 2025) matters, because
25 December 2025
 ·  ·  ·  ·  · 
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories (NYSE: ABT) finished Tuesday, Dec. 23, 2025, modestly lower, even as fresh headlines reinforced the company’s medical-device momentum heading into a holiday-shortened U.S. trading session on Wednesday, Dec. 24. ABT shares closed at $124.54 (-0.53%) and in after-hours
24 December 2025
 ·  ·  ·  ·  · 
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed
1 December 2025
 ·  ·  ·  ·  ·  · 
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact
26 November 2025
 ·  ·  ·  ·  · 
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday,
25 November 2025
 ·  ·  ·  ·  ·  · 
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the
24 November 2025
 ·  ·  ·  ·  ·  · 
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion
20 November 2025
 ·  ·  ·  ·  ·  · 
Go toTop